Treatment of Sleep Apnea to Improve Metabolic Health

Condition(s) studied

Study summary

Diabetes and prediabetes prevail among obstructive sleep apnea (OSA) patients. OSA and short sleep both detrimentally affect glycemic control regardless of obesity. With 1 in 10 adults having diabetes, 1 in 10 with prediabetes, and an estimated 600,000 affected by OSA in Sweden, attaining glycemic control is crucial. Though continuous positive airway pressure (CPAP) is the most effective treatment for OSA, its application lacks personalization, ignoring factors like comorbidities and sleep duration. Key unanswered questions regarding CPAP's impact on glycemic control include: 1) Does high CPAP adherence optimize glycemic control? 2) Should short sleep be addressed alongside OSA treatment for glycemic control? 3) Does long-term diabetes hinder CPAP's glycemic control efficacy? The purpose of this project is to enable precision health in CPAP treatment and producing a personalized treatment model for achieving glycemic control in patients with OSA, treated with CPAP. Taking advantage of a large unique patient cohort (600 patients followed over 18 months) with extensive and objective measures on CPAP adherence, OSA reduction, sleep duration, as well as information on comorbidities, anthropometric, lifestyle data, and a wide range of biomarkers related to glycemic control. This comprehensive approach and in-depth analysis will address these questions and generate a personalized treatment strategy for glycemic control in CPAP-treated OSA patients.

Eligibility

Primary outcome measure(s)

• Homeostatic model assessment for insulin resistance (HOMA-IR) — From enrollment to the end of treatment at 12 months
  Clinical marker: HOMA-IR calculated from blood glucose and serum insuling
• Glycated hemoglobin (HbA1c) — From enrollment to the end of treatment at 12 months
  Clinical maker: glycated hemoglobin (HbA1c) in % and mmol/mol
• Blood glucose — From enrollment to the end of treatment at 12 months
  Clinical marker: blood glucose in mmol/L
• Serum insulin — From enrollment to the end of treatment at 12 months
  Clinical marker: serum insulin in mU/L
• Plasma triglycerides — From enrollment to the end of treatment at 12 months
  Clinical marker: Triglycerides in mg/dL
• Plasma cholesterol — From enrollment to the end of treatment at 12 months
  Clinical marker: plasma cholesterol in mg/dL
• HDL-cholesterol — From enrollment to the end of treatment at 12 months
  Clinial marker: high-density lipoprotein (HDL) cholesterol in mg/dL
• LDL-cholesterol — From enrollment to the end of treatment at 12 months
  Clinical marker: low-density lipoprotein (LDL) cholesterol in mg/dL

Trial sites (1)

More Uppsala University trials in Sweden

Other trials for the same condition